Fragment of RegeneRx Biopharmaceuticals, Inc.’s Tß4 Inhibits Activation of Liver Cells Responsible Fibrosis & Scar Formation

ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) has announced that researchers have found that a fragment of Tß4 has the ability to inhibit a type of liver cell responsible for fibrosis and scar formation by blocking the binding of AKT to actin. AKT is an important enzyme that regulates cell death; actin is responsible for cell contraction and movement. The molecule responsible for this activity is a seven amino acid fragment of Tß4 known to be the acting binding domain of Tß4.